Controversial effect of epoetin in cancer: Grounds for a translational research exercise?

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1289-1291

  Apolone, G ^a  

^a Lab of Translational/Outcome Res   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER PATIENT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FATIGUE; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HUMAN; MULTIVARIATE ANALYSIS; OXYGENATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ANEMIA; BREAST NEOPLASMS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 2942542726     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.12.024     Document Type: Editorial

References (18)

1. Littlewood T.J. The impact of hemoglobin on treatment outcomes in patients with cancer. Semin. Oncol. 28:2001;49-53
2. Rizzo D.J., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 20:2002;4083-4107
3. Seidenfeld J., Piper M., Hassemblad C., et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of Controlled Clinical Trials. J. Natl. Cancer Inst. 93:2001;1204-1214
4. Sabbatini P. The relationship betwen anemia and quality of life in cancer patients. The Oncologist. 5:2000;19-23
5. Cella D., Zagari M., Vandoros C., Gagnon D., Hurtz H.J., Nartier J.W. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic patients when referenced to the general population. J. Clin. Oncol. 21:2003;366-373
6. Cella D., Dobrez D., Glaspy J. Control of cancer-related anemia with erytropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann. Oncol. 14:2003;511-519
7. Fallowfield F., Gagnon D., Zagari M., et al. Multivariate regression analyses of data from a randomized, double-blind, placebo-controlled study confirming quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br. J. Cancer. 87:2002;1341-1353
8. Silver D.F., Piver M.S. Effects of recombinant human erythropoietinon on the anti-tumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol. Oncol. 73:1999;280-284
9. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 24:2003;1021-1029
10. Acs G., Zhang P.J., Rebbeck T.R., Acs P., Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 95:2002;969-981
11. Thews O., Koening R., Kelleher D.K., Kutzer J., Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br. J. Cancer. 78:1998;752-756
12. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropietin on efficacy of preoperative chemotheradiation tharapy for squamosous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;705-715
13. Vaupel P., Kelleher D.K., Hockel M. Oxygenation status of malignant tumors: pathogenesisis of hypoxia and significacnce for tumor therapy. Semin. Oncol. 28:2001;29-35
14. Shasa D., George M.J., Harrison L.B. Once-weekly dosing of epoetin-alpha increrases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy concomittantly or sequentially with chemotherapy. Cancer. 98:2003;1072-1079
15. Henke M., Laszig R., Rube C., et al. Erythropietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled truial. Lancet. 362:2003;1255-1260
16. Brower V. Erythropietin may impair, not improve, cancer survival. Nature Medicine. 9:2003;1439
17. Doubts over epoetin in cancer. SCRIP 2003; no. 2896: 24.
18. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4:2003;459-460